Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Anthony Doyle is recorded as CFO at Biocryst Pharmaceuticals Inc (BCRX). Biocryst Pharmaceuticals Inc reported in an 8-K filed April 10, 2025 that Anthony Doyle resigned as Interim Principal Accounting Officer, effective April 9, 2025. Biocryst Pharmaceuticals Inc reported in an 8-K filed April 10, 2025 that Anthony Doyle resigned as Chief Financial Officer and Interim Principal Accounting Officer, effective April 9, 2025. Biocryst Pharmaceuticals Inc reported in an 8-K filed March 4, 2025 that Anthony Doyle resigned as Chief Financial Officer, effective April 9, 2025. The proxy statement of Biocryst Pharmaceuticals Inc reports total compensation of $2,141,135 for Anthony Doyle in fiscal 2025, including a base salary of $151,925. Disclosed compensation is on record for 6 fiscal years. Anthony Doyle has spoken on 20 earnings calls across 1 company, most recently for Biocryst Pharmaceuticals Inc on February 24, 2025.
“on February 28, 2025, Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025 (the “Effective Date”).”
“on February 28, 2025, Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025 (the “Effective Date”).”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
Start not stated–present
2023-07-10–2025-04-09
Start not stated–2025-04-09
Start not stated–2025-04-09
Recorded roles and call appearances connecting this person to public companies.
CFO
2023-07-10–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief Financial Officer and Treasurer | $151,925 | $2,141,135 |
| 2024 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief Financial Officer and Treasurer | $549,429 | $3,287,271 |
| 2023 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief Financial Officer and Treasurer | $528,297 | $1,790,349 |
| 2022 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief Financial Officer and Treasurer | $507,978 | $2,281,851 |
| 2021 | Biocryst Pharmaceuticals Inc (BCRX) | Chief Financial Officer and Treasurer | $490,800 | $2,890,803 |
| 2020 | Biocryst Pharmaceuticals Inc (BCRX) | Chief Financial Officer and Treasurer | $345,455 | $4,117,930 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
